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We would like to make a correction to the description
of the Becker–Balagtas method found in the 2002
International Journal of Epidemiology article by
Elbourne et al.1 The article describes methods of com-
bining parallel and cross-over trials for the purposes
of meta-analysis. In the following summary, we will
provide a revised description of the Becker–Balagtas
approach with an example of how to implement it.
The Becker–Balagtas approach is an estimation
method used in the meta-analysis of cross-over
trials with binary outcomes.1 It is considered a
marginal method because it relies on the marginal
probabilities of the outcome to estimate the odds
ratio (OR).2 Typically, a conditional approach, such
as the Mantel–Haenszel odds ratio (of the discordant
pairs), is the usual effect estimate for cross-over
trials.3 However, when summarizing results across
study designs the Becker–Balagtas approach is the
preferred method.3
To compute the Becker–Balagtas estimates, we first
define the observed cell quantities from a cross-over
trial. In the cross-over design, all subjects participate
in all treatments in successive periods where the
sequence of treatments is determined by randomiza-
tion.1 For example, some subjects are randomized to
receive placebo for the first period followed by the
active treatment in the second period, others are ran-
domized to receive the active treatment in the first
period followed by the placebo in the second period.
Each subject contributes two results for the active and
placebo treatment periods.
Binary outcomes from a cross-over trial may be
summarized as displayed in Table 1. Here, the out-
come from the trial is either success or failure and
the treatment is either active or placebo. Let s be
the number of subjects that had a success with both
treatments. Let v be the number of subjects that expe-
rienced failure with both treatments. Let t and u rep-
resent the number of subjects that had a success with
one treatment, but failed with the other. Let a and c
represent the row totals, b and d the column totals
and n the total number of subjects.1
According to the Becker–Balagtas method, we com-
pute the marginal odds ratio and variance as follows:3
ORMarginal ¼ ad
bc
varðInðORmarginalÞÞ ¼
1
a
þ 1
c
þ 1
b
þ 1
d
 
2n
where n is the within subject covariance and 
is defined as:3
 ¼ n2 ns ab
abcd
 
Additionally, the correlation coefficient (a ratio of
the covariance and the variance) can be estimated
from the table as:3
¼ ns abﬃﬃﬃﬃﬃﬃﬃﬃﬃ
abcd
p
The Becker–Balagtas estimation method is applied
when combining data from different designs in a
meta-analysis.1 For example, consider a meta-analysis
of two trials of the effect of brand name and generic
anti-epileptic drugs on seizure outcomes. The first
trial has a parallel design (independent outcomes)
and the second trial has a cross-over design (corre-
lated outcomes). Our objective is to combine the
results of these two trials into a single summary esti-
mate of the odds ratio of uncontrolled seizures for
generic anti-epileptic drugs compared with brand-
name anti-epileptic drugs.
Table 2 presents results from a trial with a parallel
design.4 A total of 60 newly diagnosed patients
were randomized to either a brand name or generic
anti-epileptic drug. Of the 45 patients randomized
to generic anti-epileptic drugs, 6 had uncontrolled
seizures as did 5 of the 15 allocated to brand-name
drugs.4
We compute the odds ratio and variance according
to the usual methods. For estimates of uncontrolled
seizures in generic versus brand name drugs, the
Table 1 2 2 table for a cross-over trial
Placebo treatment period
Success Failure
Active treatment period
Success s t a
Failure u v c
b d n
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calculations are performed as follows:3
OR ¼ 6  10
5  39 ¼ 0:31
varðInðORÞÞ ¼ 1
6
þ 1
5
þ 1
39
þ 1
10
¼ 0:49
Table 3 presents results from a different trial with a
cross-over design.5 In this case, all 20 participants
received both treatments and the order of treatment
was randomly assigned. Of the 20 participants, 2 expe-
rienced uncontrolled seizures with both the generic
and brand-name anti-epileptic drugs.5
We apply the Becker–Balagtas method by computing
the odds ratio from the marginal quantities. The vari-
ance is adjusted for the within-patient correlation
(¼ 0.67).3
ORMarginal ¼ 2  16
4  18 ¼ 0:44
varðIn½ðORM arg inalÞÞ ¼ 1
2
þ 1
18
þ 1
4
þ 1
16
 2 5:56
20
¼ 0:31
 ¼ 202 ð20  2Þ  ð2  4Þ
2  4  18  16
 
¼ 5:56
 ¼ ð20  2Þ  ð2  4Þﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2  4  18  16p ¼ 0:67
Assuming there are no other methodological con-
cerns or between study heterogeneity, we can then
combine these two estimates into one summary esti-
mate. The estimates from the two trials may be com-
bined by the usual inverse variance method for
meta-analysis.6 The summary estimate (ORpool) is a
weighted average of the two odds ratios where the
weights (w1, w2) are determined by the precision of
the estimates. The variance of the pooled estimate is a
function of the inverse of the sum of the weights.6
ORpool ¼ expðw1  InðOR1Þ þ w2  InðOR2ÞÞ
¼ expð0:39  1:18 þ 0:61  0:81Þ
¼ 0:39
varðInðORpoolÞÞ ¼ 1=ðvarðIn½ðOR1ÞÞÞ
þ 1=ðvarðIn½ðOR2ÞÞÞ
¼ 1
0:49
þ 1
0:31
¼ 0:19
InðOR1Þ ¼ 1:18
InðOR2Þ ¼ 0:81
w1 ¼
1
0:49
1
0:49 þ 10:31
¼ 0:39
w2 ¼
1
0:31
1
0:49 þ 10:31
¼ 0:61
A confidence interval (CI) for the pooled estimate is
then:
95% CI ¼ expðInðORpoolÞ  1:96 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
varðInðORpoolÞ
p
Þ
¼ ð0:16, 0:91Þ
To conclude this example, we report with 95%
confidence that the odds of seizure for generic
anti-epileptic drugs compared with brand-name
anti-epileptic drugs is between 0.16 and 0.91. Based
on these two trials, we find that the generic medica-
tions in these studies show a significantly reduced
odds of uncontrolled seizure compared with the
brand-name medications.
Note the following corrections to the formulae for
 and s given in the appendix of the original article.1
The formula for s may be applicable when the fre-
quency is unknown but the correlation is reported.
Assuming the same notation, the original formula
for  and s are:
 ¼ s ab
abcd
 
s ¼ abþ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
abcd
n
r
The correct formulae are as follows:
 ¼ n2 ns ab
abcd
 
s ¼ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
abcd
p þ ab
n
Correct application of the Becker–Balagtas method is
important to ensure accurate estimation of summary
estimates for meta-analysis. When including various
Table 3 Results from Oles et al. (cross-over design)
Brand name drugs
Uncontrolled
seizures
Controlled
seizures
Generic drugs
Uncontrolled seizures 2 0 2
Controlled seizures 2 16 18
Total 4 16 20
Table 2 Results from Kishore et al. (parallel design)
Drugs
Generic Brand name
Seizures
Uncontrolled 6 5 11
Controlled 39 10 49
Total 45 15 60
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trial designs in a meta-analysis, it is best to select a
common measurement that does not favour one
design over the other.1 Of the currently available
methods, the marginal approach (or Becker–Balagtas
method2) introduces the least bias when the
meta-analysis combines cross-over trials with parallel
trials.3
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With interest we read the Editorial by Dr Hense1
headed ‘When size matters’. We wish to compliment
Dr Hense for pointing to several problems that
mega-projects may generate. Most importantly, we
certainly agree that mega-cohorts are not a solution
to identifying and establishing causality per se.2
Moreover, we wish to complement a potential pitfall
of mega-studies, namely with regard to ‘bias’, a
term which was not mentioned in the Editorial.
Importantly, in view of the anticipated enormous visi-
bility of ‘these lighthouse projects of epidemiology’,1
it is a must to avoid the publication and dissemina-
tion of possibly biased findings.
In 2005, Ioannidis provided a convincing rationale
as to ‘why most published research findings are
false’.3 Having shown that small study group sizes
can be a reason for distorted results, he argued also
that ‘claimed research findings may often be simply
accurate measures of the prevailing bias’ (p. e124).3
Now, the probability that biased results may be re-
ported uncritically as valid findings actually increases
when precision is maximized because random error
no longer has relevant effects and is, thus, expected
to no longer mask small biases involved. In particular,
observational studies of very large sizes—designed to
measure small effects—are prone to this type of error
and have to be analysed with extra diligence via bias
estimation and adjustment procedures.4,5
Overall, a danger of sizeable studies is that large
numbers may be misunderstood as a sufficient tool
to identify truth and as an insurance against errors
that plague researchers in small(er) investigations.
Disconcertingly, the opposite may be true: indeed,
due to the lack of random error, likely involved
but uncovered biases may become a driving force for
erroneous findings and misinterpretations in mega-
studies that are conducted to measure small effects.
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